AOP-Wiki

API

All KERs

Showing 1576 to 1600 of 3164 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

3676	1312: Increase, Fatty acid β-oxidation	1446: Decrease, Coupling of OXPHOS	Oct 30, 2025	Oct 30, 2025	2 AOPs 612: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via reduced adenosine triphosphate 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production
3546	2333: Increase, Fat mass	2335: Increase, BMI	Jul 25, 2025	Jul 25, 2025	1 AOP 580: Mineralocorticoid Receptor Activation Leading to Increased Body Mass Index
1708	1501: Increase, ECM deposition	1458: Pulmonary fibrosis	Jan 16, 2018	Dec 6, 2021	None
2325	1501: Increase, ECM deposition	344: Increase, Liver fibrosis	Apr 10, 2021	Feb 1, 2025	2 AOPs 383: Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis 494: AhR activation leading to liver fibrosis
2330	1860: Excitation of intracellular water	1632: Increase in RONS	Apr 11, 2021	Apr 11, 2021	None
567	573: Increase, Energetic demands and therefore metabolic stress	574: Increased, Appetite and hunger	Nov 29, 2016	Dec 3, 2016	1 AOP 81: Increased metabolic stress contributes to abnormal foraging and leads to colony loss/failure
2778	2068: Increase, Endothelial Dysfunction	2003: Vascular remodeling	Sep 28, 2022	Sep 28, 2022	None
2784	2068: Increase, Endothelial Dysfunction	2069: Occurrence, Abnormal Vascular Remodeling	Oct 17, 2022	Aug 26, 2024	1 AOP 470: Deposition of energy leads to abnormal vascular remodeling
3373	2068: Increase, Endothelial Dysfunction	901: Infiltration, Inflammatory cells	Oct 30, 2024	Oct 30, 2024	1 AOP 462: Activation of reactive oxygen species leading the atherosclerosis
2200	1815: Increase, ER stress	1817: Apoptotic cell death	Nov 2, 2020	Nov 2, 2020	1 AOP 362: Immune mediated hepatitis
2643	1815: Increase, ER stress	1365: Increase, Apoptosis	Apr 8, 2022	Apr 8, 2022	1 AOP 447: Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways
3737	1815: Increase, ER stress	55: Cell injury/death	Feb 11, 2026	Feb 11, 2026	2 AOPs 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
116	103: Increase, EcR hyperactivation	60: Induction, Chitin degradation and resorption	Nov 29, 2016	Dec 3, 2016	None
998	103: Increase, EcR hyperactivation	988: Decrease, Circulating ETH	Nov 29, 2016	Dec 3, 2016	None
999	103: Increase, EcR hyperactivation	989: Decreased, synthesis and secretion of molting fluid proteases	Nov 29, 2016	Dec 3, 2016	None
1007	103: Increase, EcR hyperactivation	994: Decreased, Synthesis of molting fluid proteases	Nov 29, 2016	Dec 3, 2016	None
1343	103: Increase, EcR hyperactivation	1264: Increase, E75b expression	Feb 9, 2017	Feb 9, 2017	1 AOP 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1
3640	103: Increase, EcR hyperactivation	2373: Increase, Mis-timed EcR-responsive NR cascade	Sep 29, 2025	Sep 29, 2025	1 AOP 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
3642	2374: Increase, EcR antagonism	2375: Decrease, Mis-timed EcR-responsive NR cascade	Sep 29, 2025	Sep 29, 2025	2 AOPs 343: Ecdysone receptor antagonism leading to mortality via mis-timed ecdysone receptor-responsive nuclear receptor cascade 606: Ecdysone receptor antagonism leading to mortality via inhibition of chitin synthase 1
732	746: Increase, Dopaminergic activity	747: Decreased, Prolactin	Nov 29, 2016	Dec 3, 2016	1 AOP 112: Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat)
770	746: Increase, Dopaminergic activity	773: Increase, Endometrial adenocarcinomas	Nov 29, 2016	Dec 3, 2016	None
3672	746: Increase, Dopaminergic activity	602: Increased, Ataxia, paralysis, or hyperactivity	Oct 20, 2025	Oct 20, 2025	1 AOP 611: Behavioral abnormalities due to increased expression of dopamine transporter and receptor-related genes
1911	1635: Increase, DNA strand breaks	155: Inadequate DNA repair	May 19, 2019	Mar 8, 2024	4 AOPs 296: Oxidative DNA damage leading to chromosomal aberrations and mutations 272: Deposition of energy leading to lung cancer 478: Deposition of energy leading to occurrence of cataracts 644: Bulky DNA adducts leading to chromosomal aberrations and mutations
1931	1635: Increase, DNA strand breaks	185: Increase, Mutations	Jun 2, 2019	Jan 9, 2023	3 AOPs 296: Oxidative DNA damage leading to chromosomal aberrations and mutations 272: Deposition of energy leading to lung cancer 644: Bulky DNA adducts leading to chromosomal aberrations and mutations
1939	1635: Increase, DNA strand breaks	1636: Increase, Chromosomal aberrations	Jun 3, 2019	Jan 9, 2023	3 AOPs 296: Oxidative DNA damage leading to chromosomal aberrations and mutations 272: Deposition of energy leading to lung cancer 644: Bulky DNA adducts leading to chromosomal aberrations and mutations

Key Event Relationships (KERs)

All KERs